CVA Family Office’s GSK GSK Stock Holding History

CVA Family Office’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Hold	8,000	–	–	0.04%	218
2026 Q1	$442K	Hold	8,000	–	–	0.05%	193
2025 Q4	$392K	Hold	8,000	–	–	0.05%	200
2025 Q3	$345K	Hold	8,000	–	–	0.04%	214
2025 Q2	$307K	Hold	8,000	–	–	0.04%	226
2025 Q1	$310K	Hold	8,000	–	–	0.05%	208
2024 Q4	$271K	Hold	8,000	–	–	0.04%	226
2024 Q3	$327K	Hold	8,000	–	–	0.05%	191
2024 Q2	$308K	Hold	8,000	–	–	0.06%	191
2024 Q1	$343K	Hold	8,000	–	–	0.06%	180
2023 Q4	$296K	Hold	8,000	–	–	0.06%	188
2023 Q3	$290K	Sell	8,000 -202	-2%	-$7.17K	0.07%	173
2023 Q2	$292K	Hold	8,202	–	–	0.06%	174
2023 Q1	$292K	Sell	8,202 -179	-2%	-$6.26K	0.07%	172
2022 Q4	$295K	Buy	8,381 +8,179	+4,049%	+$272K	0.07%	156
2022 Q3	$6K	Hold	202	–	–	﹤0.01%	693
2022 Q2	$11K	Hold	202	–	–	﹤0.01%	628
2022 Q1	$11K	Hold	202	–	–	﹤0.01%	659
2021 Q4	$11K	Buy	+202	New	+$10.5K	﹤0.01%	628
2021 Q3	–	Sell	-202	Closed	-$10K	–	565
2021 Q2	$10K	Buy	+202	New	+$9.71K	﹤0.01%	647

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

CVA Family Office's GSK Position: Q2 2026 in Review

CVA Family Office held its GSK (GSK) position steady in Q2 2026 at 8,000 shares worth $419K. The position accounts for 0.04% of the portfolio, ranked #218.

CVA Family Office first reported a position in GSK in Q2 2021 and has held it in 20 quarters since. The position peaked at $442K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

CVA Family Office held 8,000 shares of GSK worth $419K as of Q2 2026.
CVA Family Office left its GSK share count unchanged in Q2 2026.
GSK made up 0.04% of CVA Family Office's portfolio in Q2 2026, its #218 holding.
CVA Family Office first reported a position in GSK in Q2 2021 and has held it in 20 quarters since.
CVA Family Office's GSK position peaked at $442K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.